News Headlines Article

FDA delays decision on Impax Parkinson’s drug
San Francisco Business Times

An FDA decision on a treatment for Parkinson’s disease symptoms — the first non-generic drug developed by Impax Laboratories Inc. — has been pushed back three months to January. The Hayward-based drug maker (NASDAQ: IPXL) blamed the delay on changes it made to its new drug application to the Food and Drug Administration after the agency inspected Impax’s Taiwan facility. The FDA’s new decision date on Rytary, an extended-release capsule of carbidopa and levodopa aimed at the jerky movements experienced by Parkinson’s patients, is Jan. 9.